Biomarker Testing in Early-Stage NSCLC: Informing Personalized Treatment Decisions
New to biomarker testing in esNSCLC? Begin with the overview video, then dive into the supporting tools and resources.
Developed under the direction and sponsorship of Lilly Medical Affairs and is intended for US healthcare professionals only. Distributed by Healio Strategic Solutions.
Biomarker Testing in esNSCLC: Hear Insights From Board-Certified Pathologist Dr. Soo-Ryum (Stewart) Yang
A Pathologist's Perspective: Tissue Stewardship and Multidisciplinary Collaboration in Early-Stage NSCLC
Beyond Diagnosis: Answering the Key Questions on Biomarker Testing in Early NSCLC
Explore the who, what, when, where, why, and how of comprehensive biomarker testing — an interactive reference designed for the multidisciplinary team.
The Case for Early Testing: Biomarker Opportunities Across the NSCLC Treatment Journey
Find out when to order comprehensive biomarker testing — from diagnosis through surgery, adjuvant treatment, and beyond — and discover how early testing maximizes therapy options at every stage.
Choosing the Right Test: Genomic Test Selection in Early-Stage Lung Cancer
Compare upfront CGP, single gene testing, and liquid biopsy across sample requirements, turnaround time, coverage, and cost to inform evidence-based selection for your patients.
Building Your Testing Protocol: Implementing Comprehensive Biomarker Testing in Early-Stage NSCLC
Understand the tradeoffs in designing an appropriate biomarker testing protocol for your institution.
MMAT-03076 04/2026 © 2026 Lilly USA, LLC. All rights reserved.